Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q3 EPS by 40c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $61.65 +3.56%
Financial Fact:
Change in value of derivatives: -113.36K
Today's EPS Names:
ARIS, COHR, ATS, More
Financial Fact:
Change in value of derivatives: -113.36K
Today's EPS Names:
ARIS, COHR, ATS, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q3 EPS of ($1.26), $0.40 worse than the analyst estimate of ($0.86). Revenue for the quarter came in at $27.77 million versus the consensus estimate of $53.9 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Veracyte (VCYT) Tops Q3 EPS by 10c ; Offers Guidance
- Steris (STE) Tops Q3 EPS by 26c ; Offers Guidance
- FatPipe, Inc. (FATN) Reports Q3 EPS of $0.09
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
